Actinium Pharmaceuticals Inc - Margin dodolan resik ATNM

Logo grafis Actinium Pharmaceuticals, Inc. (ATNM)

Actinium Pharmaceuticals (ATNM) is implementing high-precision radiotherapy that destroys blood tumors without damaging healthy tissues. The high authority of Iomab-B in radioimmunotherapy ensures the company's leadership in hematology. Revenues are based on the commercial rollout of this drug for transplantation preparation. The business's net margin efficiency demonstrates resilience to shocks, and the 30.30 indicator expresses the state of the sales profitability metric.

Rentabilitas dodolan resik Actinium Corp (ATNM): kanggo periode 04.07.2022 - 20.11.2026

ATNM (Actinium Corp): rincian analitis lan laporan miturut indikator

- rega saham lan konsensus proyeksi valuasi:
Analisis dhasar perusahaan:Actinium Pharmaceuticals, Inc., ATNM
Produk dadi Actinium Pharmaceuticals Inc

This indicator determines the share of net profit in total revenue, measuring the efficiency of converting income into capital. The metric allows an investor to assess operational resilience and the business's scaling potential. An analysis of the base net sales margin reveals risks of asset compression during market volatility. For Actinium Pharmaceuticals (ATNM), this figure reflects the financial readiness for the commercial launch of Iomab-B. Margin dynamics will confirm the company's ability to capture the leukemia therapy market.